Neurocrine Biosciences Inc (NBIX) Return on Investment ROI from the third quarter of 2026 to third quarter of 2025 and for the year 2026, average high and low, overall ranking from Sep 30 2026 to Sep 30 2025 - CSIMarket
CSIMarket Company Name, Ticker, Industry, else..
 


• ROA Quarterly
• ROI Quarterly
• ROE Quarterly
Neurocrine Biosciences Inc   (NASDAQ: NBIX)


Neurocrine Biosciences Inc's ROI from its third quarter of 2026 to the third quarter of 2025 and 5 Year Period

Return on Investment, Quarterly Results, Trends, Rankings, Statistics

What is Neurocrine Biosciences Inc's ROI in the third quarter of 2026?
Neurocrine Biosciences Inc achieved a return on average invested assets (ROI) of 16.94 % in its third quarter of 2026, this is above NBIX's average return on investment of -2.55%.
Neurocrine Biosciences Inc s investments during the 12 months ending in the third quarter of 2026 are valued at $4 billion

ROI fell compared to the second quarter of 2026, despite the net income growth of 43.01% from the second quarter of 2026.

Within the Healthcare sector 61 other companies had a higher return on investment. While Return on investment, overall ranking has progressed in the Sep 30 2026 quarter, so far to 381, from total ROI ranking in the second quarter of 2026 at 383.

Definition and Formula of Return on Investment


Download as CSV
Commercial Data Licensing & OEM
Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms
API & Data Feeds
Programmatic access to normalized fundamentals & ratios.

Return On Investment (Sep 30 2026)
III. Quarter		 (Jun 30 2026)
II. Quarter		 (Mar 31 2026)
I. Quarter		 (Dec 31 2025)
IV. Quarter		 (Sep 30 2025)
III. Quarter
Y / Y Investment Change TTM 24.31 % 23.48 % 20.01 % 16.47 % 16.48 %
Y / Y Net Income Change TTM 64.14 % 102.56 % 177.66 % 105.5 % 229.74 %
Investment (TTM) in Millions 4,385 4,313 4,075 3,820 3,628
Return On Investment (TTM) 16.94 % 17.82 % 17.99 % 13.72 % 12.83 %
NBIX's Overall Ranking # 381 # 383 # 163 # 119 #
Seq. Investment Change TTM 4.78 % 6.52 % 6.52 % 4.56 % 4.07 %
Seq. Net Income Change TTM -0.43 % 5.52 % 39.7 % 11.82 % 22.88 %
Net Income (TTM) in Millions 703 706 669 479 428

NBIX Company Profile >> Back to NBIX Roi Comparisons >> See Annual NBIX Return On Investment



Return On Investment NBIX's Ranking
Within: No.
Industry # 12
Sector # 62
Overall # 381

Return On Investment Statistics
High Average Low
35.39 %
-2.55 %
-58.16 %
(Dec 31 2020)   (Mar 31 2017)







Financial Statements
Neurocrine Biosciences Inc's III. Quarter Investments $ 4,385 Millions NBIX's Balance sheet
Neurocrine Biosciences Inc's III. Quarter Income $ 207 Millions Quarterly NBIX's Income Statement
NBIX's Income by Division See NBIX's Income by Division


NBIX Annual Return On Investment (Dec 31 2025)
2025		 (Dec 31 2024)
2024		 (Dec 31 2023)
2023		 (Dec 31 2022)
2022		 (Dec 31 2021)
2021
Total Investments in Millions 3,888 3,211 2,597 1,831 1,827
Y / Y Investment Growth 21.09 % 23.66 % 41.81 % 0.24 % 17.99 %
Net Income in Millions 479 341 250 155 90
Y / Y Net Income Growth 40.23 % 36.68 % 61.62 % 72.43 % -78 %
Annual Return On Investment 12.31 % 10.63 % 9.62 % 8.44 % 4.91 %


Annual Roi Comment
In the fiscal year 2025 ROI improved to 12.31 % compared to the prior year, due to net income growth.

Definition and Formula of Return on Investment

Other ROI Ratios
Biotechnology & Pharmaceuticals Industry Roi Trends and Statistics
Healthcare Sector Return On Investment Statistics
Roi Trends for overall market
NBIX's Roi Ratio versus Biotechnology & Pharmaceuticals Industry, Healthcare Sector and total Market
Highest Ranking Return On Investment
Lowest Ranking Return On Investment
Subscribers only: Roi for NBIX's Competitors
Subscribers only: Roi for Neurocrine Biosciences Inc's Suppliers
Subscribers only: Return On Investment for NBIX's Customers

Other Ratios
NBIX's Roa NBIX's Inventory Turnover Ratio NBIX's Growth Rates NBIX's Dividend Statistics
NBIX's Profitability Ratios NBIX's Asset Turnover Ratio NBIX's Dividend Growth
NBIX's Roe NBIX's Valuation Ratios NBIX's Financial Strength Ratios NBIX's Dividend Payout Ratio



Companies with similar Return On Investment at Sep 30 2026, within Healthcare Sector ROI
Aurinia Pharmaceuticals Inc   45.04 %
Nurix Therapeutics Inc   44.12 %
Medpace Holdings Inc   41.14 %
Rallybio Corporation  36.04 %
Eli Lilly And Company  32.00 %
Caredx Inc   30.65 %
Zevra Therapeutics Inc   29.88 %
Acadia Pharmaceuticals Inc   26.89 %
Protalix Biotherapeutics inc   26.06 %
Standard Biotools Inc   23.91 %
Electromed Inc   23.41 %
Iradimed Corporation  22.98 %
Corcept Therapeutics Inc  22.08 %
Resmed Inc   21.10 %
Alector Inc   20.83 %
Chemed Corporation  20.46 %
Halozyme Therapeutics Inc   19.64 %
Pro dex Inc   19.11 %
Dexcom Inc   18.92 %
Illumina Inc   18.74 %
Denali Therapeutics Inc   17.88 %
West Pharmaceutical Services Inc   17.65 %
Healthcare Services Group Inc   17.18 %
Neurocrine Biosciences Inc   16.94 %
Krystal Biotech Inc   16.91 %
Vertex Pharmaceuticals Inc  16.63 %
Sanuwave Health Inc   16.50 %
Intuitive Surgical Inc   16.30 %
Hca Healthcare Inc   15.54 %
Kiniksa Pharmaceuticals International Plc  15.45 %

Date modified: 2026-11-03T10:01:40+00:00



Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.

© 2026 CSIMarket.com — Proprietary financial dataset. All rights reserved. Redistribution or automated extraction prohibited.